Navigation Links
Pharmacyclics Reports Second Quarter 2013 Results
Date:7/31/2013

gnizes amounts incurred in excess of the annual cap ("Excess Amounts") as a reduction to operating expenses. For the three months ended June 30, 2013, the Company recognized $20.4 million of Excess Amounts as a $17.4 million reduction to research and development expense and a $3.0 million reduction to general and administrative expense.

GAAP operating expenses were $98.5 million for the six months ended June 30, 2013, compared to $39.5 million for the six months ended June 30, 2012. For the six months ended June 30, 2013, the Company recognized $20.4 million of Excess Amounts as a $17.4 million reduction to research and development expense and $3.0 million reduction to general and administrative expense. Under the Agreement, Janssen will fund maximum Excess Amounts of $225 million, which includes interest of $25 million. To date, the Company has recorded Excess Amounts of $38.5 million. The Company recognizes Excess Amounts as a reduction to operating expenses as the Company's repayment of Excess Amounts to Janssen is contingent and would become payable only after the third profitable calendar quarter for the product. Further, Excess Amounts shall be reimbursable only from the Company's share of pre-tax profits (if any) after the third profitable calendar quarter for the product.

As of June 30, 2013, the Company had cash, cash equivalents and marketable securities of $505.0 million, compared with $317.1 million as of December 31, 2012. As previously announced on July 10, 2013, the Company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, for two relapsed/refractory B-cell malignancy indications: mantle cell lymphoma (MCL) and CLL/SLL. Upon acceptance of such filing by the FDA, the Company would be entitled to receive from Janssen $75 million in regulatory milestone payments.

The Company expects to end 2013 in excess of $550 mill
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
2. Pharmacyclics Reports First Quarter 2013 Results
3. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
4. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
5. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
6. Pharmacyclics, Inc. Prices Public Offering of Common Stock
7. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
8. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
9. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
10. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has announced ... Market" report to their offering. ... focuses on the developments in the self-monitoring blood glucose ... Reimbursement analysis and the effects of competitive bidding have ... SMBG meters have been performed, based on the various ...
(Date:12/22/2014)... a privately-held medical products and technologies company, today announced ... Officer of the company, effective December 22, 2014. ... Board of Directors of ConvaTec thanks Mr. Berger for ... years," said Magnus Lundberg , the Chairman of ... company is well positioned for the future."  The company ...
(Date:12/22/2014)... /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII ... and commercializing innovative therapies addressing major unmet medical ... open letter to shareholders from President & CEO, ... Dear RXi Shareholders, In the ... posted on certain social media sites seem to ...
Breaking Medicine Technology:US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... FORT LAUDERDALE, Fla., Nov. 27 Imaging,Diagnostic Systems, ... laser,optical breast imaging, announced today that the Company ... in its CTLM(R) clinical trials.,Under an approved protocol, ... submission of a Premarket Approval (PMA) application to ...
... 10:00 a.m. (EST), A World AIDS Day Call ... and African Women,s, Faith-based and Youth Rights,Organizations Call on Congress ... Plan, WASHINGTON, Nov. 26 The following was,released by ... November 29, 2007, at 10:00 a.m. EST, Who: ...
Cached Medicine Technology:Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System 2Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System 3World AIDS Day Audio Press Conference 2
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... be closing in on a "fountain of youth" drug that ... of older adults, a new study suggests. Seniors received ... drug that targets a genetic signaling pathway linked to aging ... The experimental medication, a version of the ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as part of ... applications on the iOS, Android, and Windows markets. Andrew Tropeano, ... app review and shared with viewers how this is an ... saying goes, “A picture says a thousand words.” It’s true. ... single image, because each picture holds a unique and special ...
(Date:12/25/2014)... Each year trauma accounts for approximately ... admissions across the nation (according to the Centers ... National Hospital Ambulatory Medical Care Survey collected data ... 2010. They estimated that there were between 3.5 and ... primary diagnosis of broken bone or fracture. , ...
(Date:12/24/2014)... (PRWEB) December 25, 2014 Over 700 ... to their local communities. That is 700 smiling little ... single gift. Additionally over $6000 in monetary donations was ... offset some of the expenses they incur through the ... drive were A Child's Haven , Shrine's Children's ...
(Date:12/24/2014)... iFitDress.com, a famous dress manufacturer and retailer, has announced ... these items are brand new; they are made by experienced ... the new range of high quality prom gowns. A lot ... are made according to the latest trends. For years, the ... the company is handpicked by skilled tailors. , In the ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Many Prom Dresses under 150 from Well-known Dress Manufacturer iFitDress.com 2
... FRANCISCO, Calif., June 1 Rigel Pharmaceuticals, Inc. (Nasdaq: ... Syk inhibitor, R788, is being evaluated in a Phase ... National Cancer Institute (NCI), part of the U.S. National ... will include patients with advanced colorectal, thyroid, non-small cell ...
... Company to Divest Late Stage Operations, Signs ... INC Research, , , TORONTO, June 1 /PRNewswire-FirstCall/ - ... leading provider of products and services to the global life ... MDS Pharma Services business on the delivery of Early Stage ...
... June 1 A panoramic downtown Milwaukee view, ... to the rooftop healing garden at Aurora St. ... and sounds awaiting guests at the newly opened ... Agnes and Morland Hamilton Healing Conservatory. , ...
... ... Contacts ( www.ClearlyContacts.ca ) and Stockhouse ( www.Stockhouse.com ), are pleased to announce the ... ... 2009 -- Two Vancouver based online powerhouses, Clearly Contacts ( www.ClearlyContacts.ca ) and Stockhouse ...
... , ... regulations have forced healthcare providers, insurers, and managed care organizations to take a hard look ... industry now changes. Instead of "Do I accommodate the LEP market?" we are asking, "How ... , ...
... Infants and young toddlers with obstructive sleep apnea and ... of the ailment, according to an invited article in ... Surgery . , The study evaluated 73 cases in ... for obstructive sleep apnea through the removal of the ...
Cached Medicine News:Health News:Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers 2Health News:Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers 3Health News:MDS Announces Strategy to Focus MDS Pharma Services on Early Stage Operations - Discovery Through Phase IIa 2Health News:MDS Announces Strategy to Focus MDS Pharma Services on Early Stage Operations - Discovery Through Phase IIa 3Health News:MDS Announces Strategy to Focus MDS Pharma Services on Early Stage Operations - Discovery Through Phase IIa 4Health News:Aurora St. Luke's Dedicates Rooftop Healing Garden and Conservatory 2Health News:Aurora St. Luke's Dedicates Rooftop Healing Garden and Conservatory 3Health News:Clearly Contacts Forms Strategic Marketing Alliance with Stockhouse 2Health News:Clearly Contacts Forms Strategic Marketing Alliance with Stockhouse 3Health News:Avantpage Translations Releases White Paper on Capturing The Fastest Growing Healthcare Market In America 2
9 mm blade....
Consist of 6 disposable bevel blades (N0522) and chuck handle (0521). Malleable shafts. Designated most popular model or size....
Duckbill. 3.5 mm tip. Light curve....
1.25 mm x 2.5 mm blade. 135 degrees back scratcher. Round handle....
Medicine Products: